{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:17Z","timestamp":1786997897000,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.urolonc.2022.04.013","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T07:48:04Z","timestamp":1653292084000},"page":"410.e19-410.e27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients"],"prefix":"10.1016","volume":"40","author":[{"given":"Sungyong","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Widen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria C.","family":"Galvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhee","family":"Choi-Kuaea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo J.","family":"Eyzaguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woonyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Theodorescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"De Hoedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2683-2185","authenticated-orcid":false,"given":"Stephen B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2022.04.013_bib0001","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0002","doi-asserted-by":"crossref","first-page":"446","DOI":"10.6004\/jnccn.2013.0059","article-title":"Bladder cancer","volume":"11","author":"Clark","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0003","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0004","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol,"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0005","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.28147","article-title":"Recurrence of high-risk bladder cancer: a population-based analysis","volume":"119","author":"Chamie","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0006","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell,"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0007","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0008","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2019.04.036","article-title":"Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors","volume":"76","author":"Lotan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0009","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.juro.2010.12.049","article-title":"Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007)","volume":"185","author":"Mallin","year":"2011","journal-title":"J Urol,"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0010","first-page":"755","article-title":"Population-based assessment of racial\/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer","volume":"28","author":"Williams","year":"2017","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0011","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jamcollsurg.2005.09.009","article-title":"Gender and geographic influence on the racial disparity in bladder cancer mortality in the US","volume":"202","author":"Underwood","year":"2006","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0012","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/cncr.11942","article-title":"Survival experience of black patients and white patients with bladder carcinoma","volume":"100","author":"Prout","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0013","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0014","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0015","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.urology.2011.02.042","article-title":"Ethnic differences in bladder cancer survival","volume":"78","author":"Yee","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0016","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrurol.2018.2","article-title":"A practical guide to bladder cancer pathology","volume":"15","author":"Comp\u00e9rat","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0017","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2012.09.063","article-title":"ICUD-EAU international consultation on bladder cancer 2012: pathology","volume":"63","author":"Amin","year":"2013","journal-title":"Eur Urol,"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0018","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/PAS.0000000000000240","article-title":"Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Amin","year":"2014","journal-title":"Am J Surg Pathol,"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0019","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0021","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0022","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0023","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0024","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0025","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/gb-2006-7-10-r93","article-title":"Pathway and gene-set activation measurement from mRNA expression data: the tissue distribution of human pathways","volume":"7","author":"Levine","year":"2006","journal-title":"Genome Biol"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0026","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1038\/s41467-021-25103-7","article-title":"An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer","volume":"12","author":"Gouin","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0027","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1038\/onc.2017.149","article-title":"Fibulin-3 promotes muscle-invasive bladder cancer","volume":"36","author":"Han","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0028","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2147\/CMAR.S196450","article-title":"S100A16 regulated by Snail promotes the chemoresistance of nonmuscle invasive bladder cancer through the AKT\/Bcl-2 pathway","volume":"11","author":"Wang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205143","article-title":"A systems approach to interrogate gene expression patterns in African American men presenting with clinically localized prostate cancer","volume":"13","author":"Hardiman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1055-9965.EPI-19-0407","article-title":"Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk","volume":"29","author":"Creed","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0031","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.21037\/tau-21-158","article-title":"Genomic analysis of response to bacillus Calmette-Guerin (BCG) treatment in high-grade stage 1 bladder cancer patients","volume":"10","author":"Sanders","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0032","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0033","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1158\/0008-5472.CAN-07-6278","article-title":"Mcl-1: a gateway to TRAIL sensitization","volume":"68","author":"Kim","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2022.04.013_bib0034","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-Unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922001417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922001417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:26:26Z","timestamp":1761042386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922001417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1078143922001417"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.04.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}